Literature DB >> 1667255

Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.

N Nakanishi1, S Yoshida, H Wakebe, M Inoue, T Yamaguchi, S Mitsuhashi.   

Abstract

Mechanisms of Staphylococcus aureus resistance to fluoroquinolones were characterized. Subunit A and B proteins of DNA gyrase were partially purified from fluoroquinolone-susceptible strain SA113 and resistant isolate MS16405, which was 250- to 1,000-fold less susceptible to fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, temafloxacin, and sparfloxacin than SA113 was. The supercoiling activity of the gyrase from SA113 was inhibited by the fluoroquinolones, and the 50% inhibitory concentrations of the drugs correlated well with their MICs. In contrast, the gyrase from MS16405 was insensitive to inhibition of supercoiling by all of the quinolones tested, even at 800 micrograms/ml. Combinations of heterologous gyrase subunits showed that subunit A from MS16405 conferred fluoroquinolone resistance, suggesting that an alteration in gyrase subunit A is a cause of the fluoroquinolone resistance in MS16405. Uptake of hydrophilic fluoroquinolones such as ciprofloxacin and norfloxacin by MS16405 was significantly lower than that by SA113. Furthermore, this difference was abolished by the addition of an energy inhibitor, carbonyl cyanide m-chlorophenylhydrazone, suggesting that an alteration in an energy-dependent process, such as an active efflux of hydrophilic quinolones, may lead to decreased drug uptake and hence to increased resistance to fluoroquinolones in MS16405. These findings suggest that the fluoroquinolone resistance in MS16405 is due mainly to an alteration in subunit A of DNA gyrase and may also be associated with an alteration in the drug uptake process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1667255      PMCID: PMC245431          DOI: 10.1128/AAC.35.12.2562

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

4.  Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones.

Authors:  H Yoshida; M Bogaki; S Nakamura; K Ubukata; M Konno
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

5.  DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity.

Authors:  M Takahata; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.

Authors:  S Yoshida; T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones.

Authors:  H Aoyama; K Sato; T Fujii; K Fujimaki; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

9.  Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

Authors:  N J Robillard; A L Scarpa
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 10.  Mode of action of the quinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb
View more
  20 in total

1.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.

Authors:  A Y Saiki; L L Shen; C M Chen; J Baranowski; C G Lerner
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 4.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus.

Authors:  S M Brockbank; P T Barth
Journal:  J Bacteriol       Date:  1993-06       Impact factor: 3.490

Review 6.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

Authors:  E Wakabayashi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.

Authors:  H Wakebe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 10.  Bacterial resistance to fluoroquinolones: lessons to be learned.

Authors:  P Ball
Journal:  Infection       Date:  1994       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.